Usefulness of exosomal microRNA as a biomarker for pancreatic cancer

Research Project

Project/Area Number	16K10610
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Digestive surgery
Research Institution	Teikyo University
Principal Investigator	Wada Keita 帝京大学, 医学部, 准教授 (80349307)
Co-Investigator(Kenkyū-buntansha)	飯沼久恵帝京大学, 医学部, 講師 (30147102) 佐野圭二帝京大学, 医学部, 教授 (00334392) 三浦文彦帝京大学, 医学部, 准教授 (00344995)
Project Period (FY)	2016-04-01 – 2020-03-31
Project Status	Completed (Fiscal Year 2019)
Budget Amount *help	¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000) Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000) Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000) Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords	膵癌 / マイクロRNA / miRNA / micro RNA / micor RNA / バイオマーカー / 癌
Outline of Final Research Achievements	In order to examine the significance of microRNA (miRNA) as a biomarker in pancreatic cancer, miRNA expression was measured using a blood sample collected from a pancreatic cancer patient. First, the miRNA array was performed and compared with healthy subjects to extract miRNAs highly specific to pancreatic cancer. Next, we compared the miRNA-451a expression level with clinicopathological factors using blood samples collected before surgery for patients with resected pancreatic cancer. As a result, the miR-451a high expression group was significantly higher than the low expression group. Recurrence-free survival and shortened overall survival were observed. Similar results were obtained in portal blood samples that were perfusion of tumor, suggesting that miRNA may be a predictor of recurrence and prognosis in pancreatic cancer.
Academic Significance and Societal Importance of the Research Achievements	膵癌は難治性がんの一つであり、患者全体の5年生存率は欧米、日本で6-7%と推定されている。膵癌が予後不良であることの一因は有効な早期診断法がなく、ほぼ全例が診断された時点で進行癌であることがあげられる。膵癌治療成績の向上のためには早期診断も然ることながら、治療効果モニタリングに有用なバイオマーカーの開発が不可欠である。今回の検討でmiRNAが膵癌における有用なバイオマーカーである可能性が示されたことから、今後の研究により早期発見、危険群の選別、治療効果予測などへの応用が期待される。